News & Events
News / press releases
CORAT Therapeutics GmbH announces partnership with Dermapharm Holding SE
CORAT Therapeutics GmbH announces partnership with Dermapharm Holding SE
CORAT antibody COR-101 binds and inhibits all B.1.617 SARS-CoV-2 variants, including the fast proliferating “delta” variant
CORAT antibody COR-101 recognizes the current “Indian” mutant B.1.617
CORAT Therapeutics secures additional funding for Phase II clinical evaluation of its COVID-19 treatment
CORAT Therapeutics secures additional funding
TV report on COR-101
CORAT’s CEO Dr. Andreas Herrmann and CSO Dr. André Frenzel comment in international television on the start of clinical studies with CORAT Therapeutics SARS-CoV-2 neutralising antibody COR-101 against COVID-19 in hospitalized patients. The article can be viewed at the following link: COVID-19 Special: The challenge of developing a cure Source:...
events / conferences
events 2021
link
BIO Europe 2021
October 25 – 28, 2021 | Virtual
PEGS Boston 2021
June 10 – 18, 2021 | Virtual
Biologics Europe 2021
April 25 – 28, 2021 | Virtual